Back to search results

Growth Hormone Replacement for Gulf War Illness and Adult Growth Hormone Deficiency

This study, called GWIT, is looking at whether recombinant human growth hormone (rhGH) can help veterans who have both Gulf War Illness (GWI) and adult growth hormone deficiency (AGHD). GWI can cause symptoms like fatigue and pain, and AGHD can cause similar issues. Researchers want to see if rhGH can reduce fat around the stomach area and improve GWI symptoms. They are also trying to find out if a larger study on this treatment would be worthwhile. To join, you must be a Gulf War veteran between 18 and 64 years old, diagnosed with GWI by the study team, and have AGHD confirmed by a specific blood test. The study is currently unclear on its recruitment status and plans to enroll 20 participants.

Study design
This is an interventional study with a planned enrollment of 20 participants. It is not specified if it is randomized or blinded.
What's involved
To determine eligibility, you will complete questionnaires, blood tests, and a brain scan. The primary endpoint measures changes over six months.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at six months, indicating a follow-up period of at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05355272

Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)

Recruiting
PHASE2Ages 18–64InterventionalTreatment
Baylor College of Medicine
~20 participants
Updated 2026-05-08 on ClinicalTrials.gov
What's tested:Recombinant human growth hormone

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in truncal fat mass from baseline to six months
Measured over 6 months

Conditions

Gulf War Syndrome
Adult Growth Hormone Deficiency

Explore related trials

Adult growth hormone deficiencyGulf war syndrome

NCT05355272

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Michael E. DeBakey VA Medical Center

    Houston, Texasstudy coordinator listed

    Recruiting

  • VA Puget Sound Healthcare System

    Seattle, Washingtonstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Ricardo Jorge, MD · PRINCIPAL_INVESTIGATOR · Baylor College of Medicine

Who to contact

Lane Witkowski
[email protected]
(206) 419-1261
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Change in truncal fat mass from baseline to six months6 months

    The primary outcome measure is the difference of truncal fat mass percentage from baseline to six months. Truncal fat mass will be assessed at baseline, 3-months, and 6-months using calibrated dual energy x-ray absorptiometry (DEXA). A large mean difference corresponds with greater changes in truncal fat mass. Decreased truncal fat mass is associated with reduced risk of cardiovascular disease.